AbbVieABBV
ABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 55,000
0
Funds holding %
of 7,311 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
108% more first-time investments, than exits
New positions opened: 258 | Existing positions closed: 124
47% more funds holding in top 10
Funds holding in top 10: 165 [Q4 2024] → 242 (+77) [Q1 2025]
15% more call options, than puts
Call options by funds: $3.94B | Put options by funds: $3.43B
14% more capital invested
Capital invested by funds: $232B [Q4 2024] → $264B (+$31.7B) [Q1 2025]
1% more funds holding
Funds holding: 3,676 [Q4 2024] → 3,726 (+50) [Q1 2025]
0.98% less ownership
Funds ownership: 72.04% [Q4 2024] → 71.07% (-0.98%) [Q1 2025]
7% less repeat investments, than reductions
Existing positions increased: 1,463 | Existing positions reduced: 1,580
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$194
1%
upside
Avg. target
$215
12%
upside
High target
$250
30%
upside
7 analyst ratings
5 positive
71%
2 neutral
29%
0 negative
0%
Citigroup Geoff Meacham | 7%upside $205 | Neutral Downgraded | 14 May 2025 |
Guggenheim Vamil Divan | 12%upside $216 | Buy Maintained | 29 Apr 2025 |
Raymond James Gary Nachman | 18%upside $227 | Outperform Maintained | 28 Apr 2025 |
Evercore ISI Group Gavin Clark-Gartner | 7%upside $205 | Outperform Maintained | 28 Apr 2025 |
Morgan Stanley Terence Flynn | 30%upside $250 | Overweight Maintained | 28 Apr 2025 |
Financial journalist opinion
Based on 53 articles about ABBV published over the past 30 days
Positive
Zacks Investment Research
1 day ago
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Neutral
Seeking Alpha
1 day ago
2 ETFs To Prepare You For A Potential Recession
I see a 50-60% chance of a recession in the next 12–24 months, so portfolio preparation is essential. I recommend the iShares Gold Trust Micro as a low-cost gold ETF that has outperformed during recent uncertainty and can hedge against downturns. I also like the iShares Core Dividend Growth ETF for its quality holdings, solid dividend growth, and resilience in volatile markets.
Positive
The Motley Fool
1 day ago
3 No-Brainer Stocks to Buy in July
Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.
Positive
The Motley Fool
2 days ago
2 Dividend Stocks to Buy for Decades of Passive Income
In 2013, AbbVie (ABBV -0.93%) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (ABT 0.18%). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes.
Positive
The Motley Fool
3 days ago
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
There's a strong parallel between investing for passive income and planting an apple tree. Both require some work up front.
Positive
Zacks Investment Research
5 days ago
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Positive
Forbes
6 days ago
AbbVie Stock At $190: Premium Pricing For A Transformation Story
AbbVie (NASDAQ:ABBV) has distinguished itself as one of the top performers in the healthcare sector this year, with its stock rising by 6% while the broader S&P 500 healthcare index fell by 1%. This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.
Positive
Zacks Investment Research
6 days ago
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
Zacks Investment Research
6 days ago
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.
Positive
Zacks Investment Research
6 days ago
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.
Charts implemented using Lightweight Charts™